European Leukemia Trial Registry
Trial: MT103-203

More Details
Title Blinatumomab for the Treatmant of Minimal Residual Disease of B-precursor ALL (BLAST)
Scientific Title A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST)
Short Title MT103-203
Trialgroup GMALL
Type of Trial multicentric, open-label
Disease Acute lymphoblastic leukemia(ALL) B-Precursor ALL
Age >= 18 years
Status Follow up
Start of Recruitment 21.09.2010
Leader Bargou, Prof. Dr. med., Ralf
Contactperson

General Contact Person
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463
Email: goekbuget@em.uni-frankfurt.de

Shortprotocol Shortprotocol
Remark For further information regarding the participating sites of the MT 103-203 trial in Europe please visit www.leukemia-net.org/content/leukemias/all/all_trials/blast/
created 25.10.2010 Johannes Kraus
changed 03.05.2018 Student Studienregister
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org